Patients with metastatic castration-sensitive prostate cancer (mCSPC), who have specific genetic mutations, were found to ...

An artificial intelligence-based tool identifies patients with high-risk, nonmetastatic prostate cancer (PCa) who would most likely benefit from treatment intensification, an investigator reported at ...